Timely Intervention of Non-Invasive Ventilation (NIV) To Treat Sleep-Ordered Breathing (SDB) Causing Respiratory Insufficiency (RI) in Amyotrophic Lateral Sclerosis (ALS) Patients Is Enhanced by Implementation of Home-Based Unattended Sleep Study (HBUSS): Results of the First Quarterly Audit at the Carolinas Neuromuscular/ALS-MDA Center (P01.104)

Neurology ◽  
2012 ◽  
Vol 78 (Meeting Abstracts 1) ◽  
pp. P01.104-P01.104
Author(s):  
U. Desai ◽  
V. Langford ◽  
E. Bravver ◽  
B. Brooks
Author(s):  
Philip J. Choi ◽  
Michael Murn ◽  
Roberta Turner ◽  
Richard Bedlack

Background: Amyotrophic Lateral Sclerosis (ALS) is a terminal neuromuscular disease with patients dying within 3-5 years of diagnosis. Most patients choose to forego invasive life sustaining measures. Timing of hospice referral can be challenging given the advancement of non-invasive ventilation (NIV) technology. Objective: To describe the characteristics of patients enrolled in hospice from an ALS clinic at 1 academic medical center and to perform a cost analysis for patients who remained on ventilator support. Methods: Retrospective cross-sectional study of patients enrolled in hospice over a 2-year period. Clinical characteristics included ALS Functional Rating Scale Revised (ALSFRS-R) score, Forced Vital Capacity (FVC), use of NIV and mechanical insufflation-exsufflation (MIE), riluzole use, and length of stay in hospice. A cost analysis was performed for patients enrolled in Duke Home Care and Hospice. Results: 85 of 104 patients who died were enrolled in hospice. Median days enrolled in hospice was 84. Patients who continued on NIV had similar hospice length of stay as those on no respiratory support (88 versus 80 days, p = 0.83). Bulbar patients had a trend toward shorter length of stay in hospice than limb onset patients (71 versus 101 days, p = 0.49). Cost analysis showed that hospice maintained a mean net operating revenue of $3234.50 per patient who continued on NIV. Conclusions: Hospice referrals for ALS patients on NIV can be challenging. This study shows that even with continued NIV use, most ALS patients die within the expected 6 months on home hospice, and care remains cost effective for hospice agencies.


2021 ◽  
Author(s):  
Eleonora Volpato ◽  
Michele Vitacca ◽  
Luciana Ptacinsky ◽  
Agata Lax ◽  
Salvatore D'Ascenzo ◽  
...  

Abstract Background: Adaptation to Non-Invasive Ventilation (NIV) in Amyotrophic Lateral Sclerosis (ALS) is generally implemented in an inpatient or outpatient setting.Aims: To investigate whether adaptation to home-based NIV is as effective as outpatient one in ALS in terms of arterial carbon dioxide (PaCO2) improvement. We also evaluated as secondary outcomes NIV acceptance, adherence and patient/caregiver satisfaction, quality of life (QoL) and caregiver burden.Methods: Sixty-six ALS patients with indication for NIV were randomly assigned to two groups: 34 underwent NIV initiation at home (Home Adaptation, HA) and 32 at multiple outpatient visits (Outpatient Adaptation, OA). Respiratory function tests were performed at baseline (T0) together with blood gas analysis, which was repeated at the end of adaptation (T1) and after 2 and 6 months from T1. Overnight cardiorespiratory polygraphy was performed at T0, T2, and T3. NIV acceptance (≥5 hours/night for 3 consecutive nights) and patient's and caregiver's expertise to manage NIV by an educational learning test were measured at T1; NIV adherence (≥150 hours/month) was measured at T2 and T3. Short Form Health Survey (SF-36), Caregiver burden Inventory (CBI), Caregiver burden scale (CBS) and Zarit Burden Interview (ZBI) were performed at T0, T2 and T3.Results: Fifty-eight participants completed the study. No significant differences were found between groups in PaCO2 at T1 (p=0.46), T2 (p=0.50) and T3 (p=0.34) as in acceptance (p=0.55) and adherence to NIV at T2 and T3 (p=0.60 and p=0.75, respectively). At T2, the patients’ QoL, assessed with SF-36, was significantly better in HA than OA (p=0.01), but this improvement was not maintained up to T3 (p = 0.17). Conclusions: In ALS, adaptation to NIV in the patient’s home is effective as that performed in an outpatient setting, in terms of PaCO2 , acceptance and adherence. Improvement in quality of life was also found to be greater at home only after adaptation, opening the need for further studies to understand the role of environment with respect to NIV adherence.


Respirology ◽  
2017 ◽  
Vol 22 (6) ◽  
pp. 1212-1218 ◽  
Author(s):  
Bart Vrijsen ◽  
Bertien Buyse ◽  
Catharina Belge ◽  
Goele Vanpee ◽  
Philip Van Damme ◽  
...  

Author(s):  
Nevena Markovic ◽  
Marcus Povitz ◽  
Joanne Smith ◽  
David Leasa ◽  
Christen Shoesmith ◽  
...  

AbstractBackground: Non-invasive ventilation (NIV) improves quality of life and survival in patients with amyotrophic lateral sclerosis (ALS) and respiratory symptoms. Little is known about the patterns of NIV use over time and the impact of NIV on end-of-life decision-making in ALS. Objective: This study assessed the pattern of NIV use over the course of the disease and the timing of end-of-life discussions in people living with ALS. Method: A retrospective single-center cohort study was performed at London Health Sciences Centre. Daily NIV duration of use was evaluated at 3-month intervals. The timing of diagnosis, NIV initiation, discussions relating to do-not-attempt-resuscitation (DNAR) and death were examined. Results: In total, 48 patients were included in the analysis. Duration of NIV use increased over time, and tolerance to NIV was observed to be better than expected in patients with bulbar-onset ALS. There was a high degree of variability in the timing of end-of-life discussions in patients with ALS (356±451 days from diagnosis). In this cohort, there was a strong association between the timing of discussions regarding code status and establishment of a DNAR order (r2=0.93). Conclusion: This retrospective cohort study suggests that the use of NIV in ALS increases over time and that there remains a great deal of variability in the timing of end-of-life discussions in people living with ALS. Future prospective studies exploring the use NIV over the disease trajectory and how NIV affects end-of-life decision-making in people with ALS are needed.


Sign in / Sign up

Export Citation Format

Share Document